Abstract:Clinical Trials, Ahead of Print. Combination therapy is increasingly being explored as a promising approach for improving cancer treatment outcomes. However, identifying effective dose combinations in early oncology drug development is challenging due to limited sample sizes in early-phase clinical trials. This task becomes even more complex when multiple agents are being escalated simultaneously, potentially leading to a loss of monotonic toxicity order with respect to the dose. Traditional single-agent trial designs are insufficient for this multi-dimensional problem, necessitating the development and implementation of dose-finding methods specifically designed for drug combinations. While, in practice, approaches to this problem have focused on preselecting combinations with a known toxicity order and applying single-agent designs, this limits the number of combinations considered and may miss promising dose combinations. In recent years, several novel designs have been proposed for exploring partially ordered drug combination spaces with the goal of identifying a maximum tolerated dose combination, based on safety, or an optimal dose combination, based on toxicity and efficacy. However, their implementation in clinical practice remains limited. In this article, we describe the application of the partial order continual reassessment method and its extensions for combination therapies in early-phase clinical trials. We present completed trials that use safety endpoints to identify maximum tolerated dose combinations and adaptively use both safety and efficacy endpoints to determine optimal treatment strategies. We discuss the effectiveness of the partial-order continual reassessment method and its extensions in identifying optimal treatment strategies and provide our experience with executing these novel adaptive designs in practice. By utilizing innovative dose-finding methods, researchers and clinicians can more effectively navigate the challenges of combination therapy development, ultimately improving patient outcomes in the treatment of cancer.

A new function for drug combination dose finding trials

Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses

Local Continual Reassessment Methods for Dose Finding and Optimization in Drug-Combination Trials.

Sequential Continual Reassessment Method for Two-Dimensional Dose Finding.

A Bayesian Dose Finding Design for Oncology Clinical Trials of Combinational Biological Agents

Dynamic Ordering Design for Dose Finding in Drug‐combination Trials

Applications of the partial-order continual reassessment method in the early development of treatment combinations

Phase I Trial Design for Drug Combinations with Bayesian Model Averaging.

Adaptive designs for identifying optimal biological dose for molecularly targeted agents.

A Nonparametric Bayesian Design for Drug Combination Cancer Trials

A New Bayesian Dose-Finding Design for Drug Combination Trials

DOD-Combo: Bayesian dose finding design in combination trials with meta-analytic-predictive prior

Simultaneous Optimization of Drug Combination Dose-Ratio Sequence with Innovative Design and Active Learning

A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents

Adaptive Dose Modification for Phase I Clinical Trials

Bayesian hybrid dose-finding design in phase I oncology clinical trials.

Bayesian Dose Finding by Jointly Modelling Toxicity and Efficacy As Time-To-Event Outcomes

Time-to-event Model-Assisted Designs for Dose-Finding Trials with Delayed Toxicity

AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials